CDC Narrows Age Recommendation for RSV Vaccines in the US

The U.S. Centers for Disease Control and Prevention (CDC) has recently updated its recommendations for respiratory syncytial virus (RSV) vaccinations, narrowing the age range for those who should receive the shots. This decision comes after a thorough review of safety and efficacy data, and has significant implications for both older adults and vaccine manufacturers. In this comprehensive article, we’ll explore the latest developments in RSV vaccination, the CDC’s new guidelines, and the impact on pharmaceutical companies like GSK plc.

Also Read-Breakthrough in Prion Disease Treatment: Epigenome Editing Shows Promise

Understanding RSV and Its Impact.

Respiratory syncytial virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms. However, it can be severe, especially for infants and older adults. RSV is a leading cause of hospitalization among young children and can be particularly dangerous for older adults, causing pneumonia and other serious respiratory illnesses.

Each year in the United States, RSV leads to approximately:

  • 177,000 hospitalizations among adults 65 years and older
  • 14,000 deaths among adults 65 years and older

These statistics underscore the importance of effective prevention strategies, including vaccination.

Shifting Focus to High-Risk Groups.

Last year, the CDC advised that all individuals aged 60 and above could consider receiving an RSV vaccine after consulting with their healthcare provider. However, based on recent safety and efficacy data, the CDC’s scientific advisors have narrowed the scope of their recommendations.

The panel unanimously suggests that all Americans aged 75 and older should receive a single dose of an RSV vaccine. For those in the 60-74 age group, vaccination is now recommended only for individuals with specific serious conditions such as chronic heart or lung issues, advanced kidney disease, and diabetes with organ damage.

The CDC’s Updated Recommendations.

On June 26, 2024, the CDC’s Advisory Committee on Immunization Practices (ACIP) voted to revise its recommendations for RSV vaccination in older adults. The new guidelines are as follows:

  1. Adults 75 years and older: All individuals in this age group are recommended to receive one dose of an RSV vaccine.
  2. Adults 60-74 years old: Only those with an increased risk of severe RSV due to underlying medical conditions should receive the vaccine.

This marks a significant change from the previous recommendation, which suggested that all adults 60 and older could consider getting the RSV vaccine after consulting with their healthcare provider.

Rationale Behind the Change.

The CDC’s decision to narrow the age recommendation was based on several factors:

  • Safety and efficacy data: Recent studies have provided more detailed information about the vaccine’s performance in different age groups.
  • Risk assessment: The committee determined that the balance of benefits and risks favors vaccination more strongly in older age groups and those with specific health conditions.
  • Resource allocation: By focusing on higher-risk groups, the new recommendations aim to optimize the use of available vaccines.

Impact on Vaccine Manufacturers.

The CDC’s updated recommendations have had a significant impact on pharmaceutical companies producing RSV vaccines, particularly GSK plc.

GSK’s Arexvy Vaccine.

GSK’s RSV vaccine, Arexvy, was initially approved by the FDA in May 2023 for adults 60 years and older. In a recent development, the FDA expanded its approval to include adults aged 50-59 who are at increased risk of severe RSV.

However, the CDC’s new recommendations do not currently include this expanded age group, which could potentially affect GSK’s market for the vaccine. The company had projected annual sales of over £3 billion ($3.79 billion) for Arexvy over time.

Market Response.

The narrowed recommendations have had an immediate impact on GSK’s stock price, with shares sliding more than 6% following the CDC announcement. This reaction reflects investor concerns about the potential reduction in the eligible patient population for Arexvy.

Competing Vaccines and Market Dynamics.

While GSK’s Arexvy was the first RSV vaccine to market, it’s not the only player:

  • Pfizer: Also has an approved RSV vaccine for older adults.
  • Moderna: Received FDA approval for its RSV vaccine, mRESVIA, in May 2024.

The competition among these manufacturers is likely to intensify as they navigate the new CDC recommendations and seek to differentiate their products.

Moderna’s mRESVIA: Efficacy Concerns and Market Entry.

Moderna’s entry into the RSV vaccine market with the FDA approval of mRESVIA has raised concerns over its efficacy. Recent data presented to the CDC showed lower effectiveness compared to GSK’s and Pfizer’s vaccines, raising questions about long-term efficacy.

While Moderna’s vaccine showed lower efficacy rates, GSK and Pfizer reported higher effectiveness in preventing severe RSV. Analysts caution against direct comparisons, highlighting differences in study timelines for these vaccines.

Clinical Data and Efficacy.

Understanding the efficacy of these vaccines is crucial for both healthcare providers and potential recipients. Here’s a brief overview of the available data:

  • GSK’s Arexvy: Showed 82.6% efficacy against RSV-related lower respiratory tract disease in adults 60 and older. Efficacy remained at 78% in the second RSV season.
  • Pfizer’s Abrysvo: Demonstrated 66.7% efficacy against RSV-related lower respiratory tract illness with 2 or more symptoms in adults 60 and older.
  • Moderna’s mRESVIA: Reported 50% efficacy in preventing RSV for 18 months in adults 60 and older.

It’s important to note that these trials were not conducted head-to-head, and differences in study design and case definitions make direct comparisons challenging.

Ongoing Research and Future Directions.

The field of RSV vaccination is rapidly evolving, with ongoing research aimed at expanding protection to broader populations:

  • Younger adults at risk: GSK is conducting trials to evaluate Arexvy’s safety and efficacy in adults aged 18-49 who are at increased risk of severe RSV.
  • Immunocompromised individuals: Studies are underway to assess the vaccine’s performance in adults with weakened immune systems.
  • Long-term protection: Researchers are investigating the duration of protection provided by these vaccines, with data on three RSV seasons expected in the future.

Public Health Implications.

The CDC’s updated recommendations have several important public health implications:

  • Targeted protection: By focusing on the highest-risk groups, the new guidelines aim to maximize the impact of vaccination efforts.
  • Healthcare resource allocation: The narrowed recommendations may help healthcare systems prioritize vaccine distribution more effectively.
  • Increased awareness: The changes highlight the importance of RSV as a serious health threat for older adults, potentially leading to improved prevention and treatment strategies.

Challenges and Considerations.

While the new recommendations provide clearer guidance, they also present some challenges:

  • Public understanding: Communicating the changes effectively to the public and healthcare providers will be crucial to ensure appropriate vaccine uptake.
  • Individual risk assessment: For adults aged 60-74, determining who is at increased risk may require careful evaluation by healthcare providers.
  • Vaccine access: Ensuring equitable access to RSV vaccines for recommended groups will be an important consideration for public health officials.

The Role of Healthcare Providers.

Healthcare providers play a critical role in implementing the new RSV vaccine recommendations:

  • Patient education: Informing patients about RSV risks and the benefits of vaccination, particularly for those in high-risk groups.
  • Risk assessment: Evaluating individual patients’ risk factors to determine if vaccination is recommended, especially for those aged 60-74.
  • Vaccine administration: Ensuring proper storage, handling, and administration of RSV vaccines.
  • Monitoring: Watching for and reporting any adverse events following vaccination to contribute to ongoing safety surveillance.

Global Perspective.

While this article focuses on U.S. recommendations, it’s worth noting that RSV is a global health concern. Many countries are developing their own vaccination strategies based on local epidemiology and healthcare resources. As more data becomes available, we may see further refinement of RSV vaccination recommendations worldwide.

Future Outlook.

The field of RSV vaccination is likely to continue evolving rapidly:

  • Expanded indications: As more data becomes available, we may see recommendations expand to include younger adults at high risk.
  • Combination vaccines: Research is ongoing into the possibility of combining RSV vaccines with other respiratory virus vaccines, such as influenza.
  • Improved formulations: Future generations of RSV vaccines may offer longer-lasting protection or better efficacy across different age groups.
  • Pediatric vaccines: While this article focuses on adult vaccination, research into RSV vaccines for infants and young children is also progressing.


The CDC’s decision to narrow the age recommendation for RSV vaccination represents a significant shift in public health strategy. By focusing on the highest-risk groups, these new guidelines aim to optimize the use of available vaccines and provide the greatest benefit to those most vulnerable to severe RSV disease.

For older adults and their healthcare providers, these changes underscore the importance of individualized risk assessment and shared decision-making when it comes to RSV vaccination. As research continues and more data becomes available, we can expect further refinements to these recommendations in the future.

The impact on vaccine manufacturers like GSK highlights the complex interplay between scientific evidence, public health policy, and market dynamics in the pharmaceutical industry. As competition in the RSV vaccine market intensifies, we may see further innovations that could ultimately benefit patients and public health.

As we navigate this evolving landscape, ongoing communication between public health officials, healthcare providers, and the public will be crucial to ensure that those who can benefit most from RSV vaccination have the opportunity to do so.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional regarding your specific medical situation and vaccination needs.


Hi there!I'm C.K. Gupta, the founder and head writer at With a passion for health and wellness, I created FitnTip to share practical, science-backed advice to help you achieve your fitness goals.Over the years, I've curated valuable information from trusted resources on topics like nutrition, exercise, weight loss, and overall well-being. My aim is to distill this knowledge into easy-to-understand tips and strategies you can implement in your daily life.Whether you're looking to get in shape, eat healthier, or simply feel your best, FitnTip is here to support and guide you. I believe that everyone has the potential to transform their health through sustainable lifestyle changes.When I'm not researching the latest health trends or writing for FitnTip, you can find me trying out new fitness routines, experimenting with nutritious recipes, and spending quality time with loved ones.I'm excited to have you join our community as we embark on this wellness journey together. Let's make positive, lasting changes and unlock a healthier, happier you!

Related Articles

Back to top button